Influencing Drug Prices through Formulary-Based Policies: Lessons from New Zealand

Research

Related Publications

Suter E, Misfeldt R, Mallinson S, Wilhelm A, Boakye O, Marchildon G, et al. Comparative Review of the Policy Landscape of Team-based Primary Health Care Service Delivery in Western Canada. Alberta Health Services; 2014.
Laberge M, Pang J, Walker K, Wong ST, Hogg W, Wodchis WP. QUALICOPC (Quality and Costs of Primary Care) Canada: A focus on the aspects of primary care most highly rated by current patients of primary care practices. Ottawa, ON: Canadian Foundation for Healthcare Improvement; 2014.
McGregor MJ, Abu-Laban RB, Ronald L, McGrail KM, Andrusiek D, Baumbusch J, et al. Nursing Home Characteristics Associated with Resident Transfers to Emergency Department. Canadian Journal on Aging. 2012;33(1):38-48.
Koehoorn M, McLeod CB, Fan JK, McGrail KM, Barer ML, Cote P, et al. Do private clinics or expedited fees improve wait- or return-to-work times for injured workers following knee surgery? Healthcare Policy. 2011;5(3):17-26.
Sutherland JM, Barer ML, Evans RG, Crump RT. Will paying the piper change the tune? Healthcare Policy. 2011;6(4):16-24.

Publication Topics

Influencing Drug Prices through Formulary-Based Policies: Lessons from New Zealand

Title
Publication TypeJournal Article
Year of Publication2007
AuthorsMorgan SG, Hanley G, McMahon M, Barer ML
JournalHealthcare policy = Politiques de santeHealthc.Policy.
Volume3
Issue1
Pagese121 - 40
Date Published2007
AbstractA national formulary has been proposed as a priority element of Canada's National Pharmaceuticals Strategy. We review a variety of formulary-based policies that might be used in conjunction with a national formulary, drawing on the policies and practices of the Pharmaceutical Management Agency of New Zealand. We consider the potential price impact of an actively managed national formulary by conducting a Canada-New Zealand price comparison for equivalent products in the four largest drug classes: statins, angiotensin-coverting enzyme (ACE) inhibitors, selective serotonin reuptake inhibitors (SSRIs) and proton pump inhibitors (PPIs). The results suggest that potential price savings for Canada in these drug classes are on the order of 21% to 79%. Such price differences would translate into billions of dollars in annual savings if applied across Canada, potentially offsetting the costs of the expansion of pharmacare coverage necessary to achieve both equity and efficiency goals in this sector.
Citation Key431